SAL0140 tablets approved for clinical trials for the treatment of chronic kidney disease
December 4, 2025
Source: drugdu
42
People's Financial News, December 3, 2025 – Salubris Pharmaceuticals (002294) announced today that the company has received the Clinical Trial Approval Notice issued by the National Medical Products Administration (NMPA), agreeing to conduct clinical trials for its independently developed innovative small molecule drug, SAL0140 tablets, for the treatment of chronic kidney disease (CKD).
SAL0140 is an aldosterone synthase inhibitor with independent intellectual property rights belonging to the company. The planned indications for development include uncontrolled hypertension (including resistant hypertension), primary aldosteronism, and chronic kidney disease (CKD), among others.
https://finance.eastmoney.com/a/202512033581668270.html
By editor
Copyright©2025 Ddu. All rights reserved.
Read more on
- Breaking the Mold and Forging a New Path! From Insulin Technology Pioneer to Global Innovation Competitor December 4, 2025
- A subsidiary of Kingfriend Pharmaceutical Co., Ltd. has received FDA approval for its self-developed injectable dapavancin December 4, 2025
- Major ophthalmic new drug successfully completed Phase III trials December 4, 2025
- Simcere Pharmaceutical and Wangshan Wangshui have reached an exclusive licensing agreement for deuterium remidevir hydrobromide for new indications such as RSV infection December 4, 2025
- Self-developed innovative drug FXS0887 approved for clinical trials in advanced malignant solid tumors December 4, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
